A SampleManager workflow is not the laboratory’s approved procedure

Link every workflow to an approved source procedure

Thermo Fisher Scientific's official record says SampleManager can automate laboratory workflows and provide step-by-step execution guidance. The direct answer is that those steps should point to an approved procedure rather than become the procedure by default. A configured sequence can omit a condition, use the wrong limit, simplify a calculation, present an outdated instruction, or apply a general method to a sample type for which the laboratory has not approved it.

The workflow master should preserve the procedure or method identifier, title, version, effective date, approved scope, sample and product types, instruments, reagents, calculations, specifications, required controls, acceptance criteria, attachments, authors, reviewers, approval record, and accountable owner. The configuration should have its own version and mapping to source clauses. Any intentional difference needs documented rationale and approval instead of being hidden as a screen-design choice.

Control version, training, and effective use

Approval of a procedure does not prove that the correct workflow reached every user at the correct time. Release controls should define when the new version becomes available, whether in-progress work finishes under the prior version, how superseded steps are blocked, which sites and instruments are in scope, and what happens when an interface or mobile device is offline. The system should retain the procedure and workflow versions actually used for each execution.

Training and authorization need the same precision. A user may be generally qualified for a method but not trained on a changed step, specific instrument, sample class, hazard, or calculation. Role-based access can enforce a configured rule, but competence and authorization remain evidence-based laboratory decisions. Exceptions such as emergency work, supervised execution, retraining, or temporary restriction should be visible, approved, time-bounded, and linked to the result record.

Preserve execution evidence and deviations

A completed sequence should show more than checked boxes. Retain who performed each critical action, timestamps, instrument and software identifiers, input and output data, sample and aliquot identity, reagent and standard lots, environmental conditions where relevant, observations, calculations, attachments, electronic signatures, and the procedural history described by the product record. Required steps should not be backfilled invisibly after work is complete.

When actual work departs from the workflow, the system should create a deviation rather than force a false match. Record the step, observed condition, immediate action, affected samples or results, authorization, investigation link, impact assessment, disposition, and any corrective or change-control action. Scientific and quality reviewers should be able to distinguish execution evidence, automated checks, analyst interpretation, and final approval without treating workflow completion as result validity.

Keep SampleManager claims inside the official record

The registered Thermo Fisher Scientific page establishes current provider positioning for SampleManager LIMS, integrated laboratory-execution guidance, flexible workflow automation, procedural histories, SDMS, ELN, analytics, access controls, and enterprise or instrument connectivity. It says the system is designed to support specified compliance and data-integrity needs. It does not establish a laboratory's validation, procedure approval, method suitability, analyst competence, data integrity, result validity, or regulatory acceptance.

Lab Systems Index reviewed the registered source on August 18, 2026 and did not operate a laboratory deployment. Buyers should verify current workflow design, procedure mapping, version release, training prerequisites, electronic signatures, raw-data links, calculations, specifications, deviations, offline behavior, audit trails, review states, validation evidence, integrations, retention, export, and service dependencies using representative regulated and non-regulated work.

Enterprise buyer test

Translate this change into the exact population, record type, workflow stage, decision owner, effective date, and evidence that could be affected. Ask current or prospective providers to demonstrate the named workflow with representative data and an exception—not a polished feature tour. Record what official documentation establishes, what a provider states, what the team observes, and what remains unresolved.

A defensible review also identifies the dependency outside the product. Authority interpretation, policy configuration, data quality, integrations, human judgment, approval rights, release governance, training, and retained evidence may remain customer or service responsibilities. The evaluation should preserve those boundaries instead of treating a technology claim as the complete operating model.

What we will watch next

Lab Systems Index will watch the named source and affected market records for later evidence that changes status, scope, availability, implementation timing, workflow consequence, or the limits of the initial report. A later announcement does not silently overwrite this dated account; the change ledger preserves the sequence.